Recent major developments for Artiva Biotherapeutics (NASDAQ: ARTV) highlight clinical data presentations for its lead candidate AlloNK at the European Alliance of Associations for Rheumatology congress, showcasing deep B-cell depletion in refractory autoimmune conditions. Additionally, the company secured FDA Regenerative Medicine Advanced Therapy (RMAT) designation for refractory rheumatoid arthritis and completed a major $300 million public stock offering.
MBM Resources Berhad (MBMR) is a prominent Malaysian investment holding company with core operations heavily anchored in the domestic automotive sector. The group maintains major strategic investments across vehicle manufacturing, motor vehicle assembly, dealership networks (most notably its significant stake in Perodua), and the production of auto parts such as alloy wheels and safety components.